tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Merus NV Faces Uncertainty and Risks Amid Genmab A/S Transaction Delays
PremiumCompany AnnouncementsMerus NV Faces Uncertainty and Risks Amid Genmab A/S Transaction Delays
1M ago
Merus NV (MRUS) Q3 Earnings Cheat Sheet
Premium
Pre-Earnings
Merus NV (MRUS) Q3 Earnings Cheat Sheet
1M ago
Merus N.V.’s Zenocutuzumab Study Termination: Market Implications
Premium
Company Announcements
Merus N.V.’s Zenocutuzumab Study Termination: Market Implications
1M ago
Cautious Optimism for Merus’s Petosemtamab in mCRC Amidst Limited Data, Hold Rating Maintained
PremiumRatingsCautious Optimism for Merus’s Petosemtamab in mCRC Amidst Limited Data, Hold Rating Maintained
2M ago
Oppenheimer positive on CytomX after Merus colon cancer data
Premium
The Fly
Oppenheimer positive on CytomX after Merus colon cancer data
2M ago
Hold Rating on Merus’s Petosemtamab: Awaiting More Data for Colorectal Cancer Efficacy
Premium
Ratings
Hold Rating on Merus’s Petosemtamab: Awaiting More Data for Colorectal Cancer Efficacy
2M ago
Unusually active option classes on open October 2nd
PremiumThe FlyUnusually active option classes on open October 2nd
2M ago
Balanced Hold Rating Amid Genmab’s Acquisition of Merus and Anticipated CRC Data
Premium
Ratings
Balanced Hold Rating Amid Genmab’s Acquisition of Merus and Anticipated CRC Data
2M ago
Hold Rating on Genmab’s Acquisition of Merus Reflects Fair Valuation and Limited Upside Potential
Premium
Ratings
Hold Rating on Genmab’s Acquisition of Merus Reflects Fair Valuation and Limited Upside Potential
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100